Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/24011—Flaviviridae
  • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
  • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/24011—Flaviviridae
  • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
  • C12N2770/24251—Methods of production or purification of viral material

Definitions

• the present invention relates to a method for the isolation of hepatitis C virus.
• the method comprises the separation of particles termed exosomes from the blood plasma of an individual infected with hepatitis C virus (HCV) and extracting RNA from these exosome particles.
• HCV hepatitis C virus
• HCV (previously known as Non-A Non-B hepatitis - NANBV) is a positive sense RNA virus of about 10000 nucleotides with a single open reading frame encoding a polyprotein of about 3000 amino acids.
• the structure of the virus has been elucidated by recombinant DNA techniques (European patent application EP-A-0318216 and European patent application EP-A-0388232), the virus itself has not been isolated and the functions of the various viral proteins produced by proteolysis of the polyprotein have only been inferred by analogy with other similar viruses of similar genomic organisation (Choo et al PNAS US A ( 1991 ) 88 2451 -2455).
• the viral proteins are all available in recombinant form, expressed in a variety of cells and cell types, including yeast, bacteria, insect, plant and mammalian cells (Chien, D.Y. et al PNAS USA (1992) 89 1001 1 -10015 and Spaete, R.R. et al Virology ( 1992) 188 819-830).
• El and E2 Two proteins, named El and E2 (corresponding to amino acids 192-383 and 384-750 of the HCV polyprotein respectively, numbered relative to the HCV-1 isolate) have been suggested to be external proteins of the viral envelope which are responsible for the binding of virus to target cells.
• HCV research is hindered very considerably by the limited host range of the virus.
• the only reliable animal model for HCV infection is the chimpanzee.
• Study of HCV life cycle has also been limited by the lack of an efficient cell culture system.
• attempts to purify HCV from biological materials such as plasma and liver have failed.
• a method for the preparation of HCV comprising separating exosome particles from the supernatant of a cellular culture infected with HCV and extracting RNA from the exosome particles.
• the exosome particles are separated from the plasma of an individual infected with HCN.
• Exosomes are subcellular organelles that result from the fusion of endocytic compartments , termed MIICs (MHC class II-enriched compartments) with the plasma membrane. These compartments have been shown to exist in antigen-presenting cells (APCs), and form a site for the localisation of the majority of intracellular MHC class II molecules ( ⁇ eefjes et al. , 1990). MIICs are endocytic vacuoles with internal membrane vesicles and sheets, and are thought to represent the subcellular site at which MHC class II molecules bind peptides (Harding et al., 1993). MIICs contain internal vesicles (exosomes) that probably originate from the inward vesiculation of its limiting membrane. When MIICs fuse with the plasma membrane, inserting MHC class II molecules into this structure, the exosomes are released into the extracellular space.
• APCs antigen-presenting cells
• Exosome particles have now been found in cell culture medium from a variety of APCs, such as dendritic cells, tonsil B cells, monocytes and macrophages (Raposo et al, 1996). These exosomes have been characterised by Geuze and coworkers (Escola, 1998) and found to be selectively enriched in some surface molecules, including certain tetraspanin membrane proteins.
• atant of a cellular culture is meant the supernatant of any fluid in which cells infected with HCV are grown.
• Suitable fluids include bodily fluids such as blood, and growth medium in which cells are cultured in vitro.
• exosomes may be prepared from the cell culture supernatant of cell lines derived from patients infected with HCV. Such cell lines may be expanded from individual cells isolated from patients infected with HCV and propagated in vitro.
• exosomes may be isolated from the plasma fraction of an individual infected with HCV. Techniques for the separation of plasma from blood will be clear to the skilled reader.
• exosomes may be any animal susceptible to infection by HCV. Suitable animals include primates, preferably higher primates such as chimpanzees and humans. Most preferably, exosomes are prepared from human patients.
• Exosome particles may be prepared from cell culture supernatant using any suitable technique, as will be clear to those of skill in the art. Examples include preparation by differential centrifugation, and using techniques of immunochemistry discussed below . Preferably, exosomes are prepared by differential centrifugation, according to the technique of Raposo et al. ( 1996).
• a method for the preparation of HCN R ⁇ A comprising the sequential steps of centrifuging plasma obtained from an individual infected with HCV to give a pellet that is enriched in exosomes, and isolating said R ⁇ A from said exosomes.
• the centrifugation is performed sequentially in iterative steps. These steps involve centrifugation firstly at approximately 200 x g, then at approximately 500 x g, at approximately 2000 x g, at approximately 10000 x g, and at approximately 70000 x g.
• Samples of pellets obtained at each centrifugation step can be analysed to assess the degree of exosome content and thus to gauge the purity of the exosome preparations.
• the preparation process can in this way be optimised.
• One technique that is suitable for analysing exosome content is by SDS-PAGE and Western blotting, using antibodies directed against proteins that are specific markers for exosome particles.
• anti-CD8 1 monoclonal antibody can be used as the primary antibody
• a labelled anti-mouse IgG can be used as the secondary antibody.
• exosomes may be prepared as followed.
• Cell cultures are first centrifuged for 10 minute at 200 x g and recovered cells represent pellet PI .
• Removed supernatant is centrifuged twice for 10 minute at 500 x g; the two pellets are pooled and represent pellet P2.
• Supernatants are sequentially centrifuged at 2000 x g twice for 15 minute (pooled pellets are referred to as P3), once at 10000 x g for 30 minute (recovered pellet represents pellet P4) and once at 70000 x g for 60 minute (yielding pellet P5).
• Samples of each pellet are then analysed in SDS-PAGE and Western blotting by using anti-CD81 monoclonal antibody followed by peroxidase-labelled anti- mouse IgG.
• the cell culture supernatant may be incubated with beads coated with, antibody that recognises marker molecules on the surface of exosome particles.
• antibody that recognises marker molecules on the surface of exosome particles For example, anti-CD81 and/or anti-CD82 antibodies may be used in this respect.
• magnetic beads such as those manufactured by Dynabeads , Dynal, Oslo, Norway, or polystyrene beads(for example, those made by Pierce) are particularly suitable in this embodiment of the invention.
• Other alternatives for the purification of exosomes include the use of sucrose density gradients or organelle elecrophoresis T lp et aL, 1994).
• RNA extraction kits may be used for convenience, such as the viral extraction kit sold by Qiagen, which uses silica gel based spin columns that allow purification of viral nucleic acids from cell-free body fluids.
• the HCV particles are prepared according to any one of the methods described above. Due to technical difficulties involved in the preparation of HCV particles, no composition of purified HCV particles have yet been made.
• the method of the invention thus allows, for the first time, purified HCV particles to be prepared .
• the method of the invention therefore allows, for the first time, the biochemical and biophysical characterisation of HCV particles and proteins.
• Purified HCV particles prepared according to the invention may be used in numerous applications, as the skilled reader will appreciate. Such applications include the diagnosi , prevention and treatment of individuals infected with HCV and the development and design of agents useful in therapy, prevention and diagnosis of this disease and its progression.
• a method of diagnosing an individual as being infected with HCV comprising obtaining a preparation of cells from the individual, preparing exosome particles from the cellular supernatant and testing the exosome particles for the presence of HCV RNA and proteins.
• the preparation of cells obtained from the individual is a blood plasma preparation.
• Figure 1 shows a Western blot demonstrating exosome purification from HepG2 cell culture medium by differential centrifugation steps.
• Figure 2 shows a Western blot demonstrating exosome purification from human plasma by differential centrifugation steps.
• Figure 3 shows a Western blot demonstrating exosome capture and sorting by anti-CD81 - coated magnetic beads.
• Figure 4 shows a Western blot demonstrating exosome capture and sorting by anti-CD82- coated magnetic beads.
• Figure 5 shows a Western blot demonstrating exosome capture from HCV-infected patients.
• exosomes were isolated from several cell lines, including hepatocellular carcinoma cell lines (HepG2 and HuH7) and EBV-transformed B cell lines.
• Cell cultures were first centrifuged for 10 min at 200 x g and recovered cells represent pellet PI . Removed supernatant was centrifuged twice for 10 min at 500 x g; the two pellets were pooled and represent pellet P2.
• Supernatants were sequentially centrifuged at 2000 x g twice for 15 min (pooled pellets are referred to as P3), once at 100OO x g for 30 min (recovered pellet represents pellet P4) and once at 70000 x g for 60 min (yielding pellet P5).
• Pellet PS was found to be the fraction enriched in exosomes (see Figure 1).
• HepG2 and HuH7 hepatocellular carcinoma cell lines
• EBV-transformed B cell lines normal human plasma was subsequently assessed for the presence of exosomes.
• Diluted plasma recovered after blood separation on Ficoll gradients was processed according to the differential centrifugation protocol described above and exosomes were visualised by Western blot using anti-CD81 or anti-CD82 mAbs and peroxidase-labelled anti-mouse IgG. It has been found that there are exosomes in the plasma of healthy individuals (see Figure 2).
• exosomes can now be isolated from plasma of HCV- infected patients enriched in HCV RNA.
• the experimental approach is as follows.
• Plasma from HCV-infected human blood recovered after Ficoll separation is processed following the differential centrifugation protocol described above.
• the exosome-enriched supernatant collected from the centrifugation step at 10000 x g is incubated overnight with anti-CD81 -coated magnetic beads.
• HCV-infected plasma may be centrifuged at 20000 x g before overnight incubation with anti-CD81 - coated magnetic beads. Magnetic beads are then washed three times in 1 % BSA in 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, and 100 mM NaCl (TEN) buffer by magnetic separation and viral RNA are extracted with the Viral Extraction Kit (Qiagen). Quantitative RT-PCR for HCV RNA is performed as previously described (Pileri et al, 1998).
• Exosomes in human plasma are enriched in HCV RNA and/or structural proteins.
• Example 3 Isolation of exosomes from the blood of HCV-infected patients
• HCV RNA has been detected using quantitative RT PCR (see Table below).
• Plasma from HCV-infected human blood recovered after Ficoll separation was processed following the differential centrifugation protocol described above.
• the exosome-enriched supernatant collected from the centrifugation step at 10000 x g was incubated overnight with anti-CD81 or anti-CD82 coated magnetic beads (20 ⁇ g of purified monoclonal antibody/2, 5x 10 7 magnetic beads (Dynal). Magnetic beads were then washed three times in 1 % BSA in phosphate buffer by magnetic separation and viral RNA was extracted with the Trizol reagent (Life Technology).

Landscapes

• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Virology (AREA)
• Medicinal Chemistry (AREA)
• Wood Science & Technology (AREA)
• Gastroenterology & Hepatology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Microbiology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Saccharide Compounds (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Peptides Or Proteins (AREA)
• Steroid Compounds (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=10864765

Family Applications (1)

Country Status (13)

Cited By (21)

Families Citing this family (69)

Citations (5)

Family Cites Families (5)

• 1999
  • 1999-11-18 GB GBGB9927320.3A patent/GB9927320D0/en not_active Ceased
• 2000
  • 2000-11-20 US US10/130,467 patent/US7198923B1/en not_active Expired - Lifetime
  • 2000-11-20 DE DE60036403T patent/DE60036403T2/de not_active Expired - Lifetime
  • 2000-11-20 EP EP00979837A patent/EP1230347B1/en not_active Expired - Lifetime
  • 2000-11-20 ES ES00979837T patent/ES2292489T3/es not_active Expired - Lifetime
  • 2000-11-20 CA CA2392075A patent/CA2392075C/en not_active Expired - Lifetime
  • 2000-11-20 JP JP2001538480A patent/JP4675017B2/ja not_active Expired - Fee Related
  • 2000-11-20 AU AU17218/01A patent/AU1721801A/en not_active Abandoned
  • 2000-11-20 DK DK00979837T patent/DK1230347T3/da active
  • 2000-11-20 WO PCT/IB2000/001801 patent/WO2001036601A1/en not_active Ceased
  • 2000-11-20 AT AT00979837T patent/ATE373084T1/de active
  • 2000-11-20 PT PT00979837T patent/PT1230347E/pt unknown
• 2007
  • 2007-01-30 US US11/699,925 patent/US7807438B2/en not_active Expired - Fee Related
  • 2007-12-07 CY CY20071101559T patent/CY1107521T1/el unknown

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events